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A comment on the paper presented by Professors David Lange,
Duke University, and J.H. Reichman, Vanderbilt University.
JOSEPH STRAUS*
I.  INTRODUCTION
It is generally acknowledged that our society has a continuous
need for technological innovations.  Without new discoveries and in-
ventions and their resulting marketable processes and products, our
future would be endangered.  The shortage of food, incurable ill-
nesses, the ever increasing ozone hole, and a need for more energy,
to name but a few, are all awaiting solutions to be provided by physi-
cians, biologists, geneticists, chemists, physicists, mechanical engi-
neers, and other representatives of natural and engineering sciences.  
While these problems seem quite apparent, it is less apparent
that technical innovations alone will sufficiently master the complex
set of problems surrounding the research in new technologies.  Their
development, implementation, exploitation, transfer, and financing
within a given national economy and the potential of technical inno-
vations to serve as a cure-all, is even less clear when the problems in-
volve different national economies.  To reach these goals, a number
of economic, legal, and social issues have to be successfully resolved.
For example, some of these issues might be adequately addressed by
a regime that reflectively protects intellectual property rights, suffi-
ciently provides favorable tax treatment for research and develop-
ment (R&D) activities, and adequately circumvents bureaucratic in-
*  Dr. jur., Professor of Law, Universities of Ljubljana and Munich; Head of Depart-
ment, Max-Planck-Institute for Foreign and International Patent, Copyright and Competition
Law, Munich.
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efficiencies in the approval and maintenance of new production sites.
These key legal features, however, are only one part of the con-
ditions that decisively influence enterprises—especially the large
multinational enterprises—to engage in business in a specific country.
Other key features that generate spillovers include a country’s finan-
cial, educational, and management systems, and the degree of com-
petitive rivalry within that nation.1  Furthermore, globalization in-
volves interaction between the mobilization of resources on a
worldwide scale and the international dimension of economic compe-
tition.  As major actors in this process, multinational enterprises con-
trol and coordinate value-added activities across national boundaries,
via foreign direct investment, international trade of intermediate
goods, and inter-firm agreements.2  All of these key features must be
satisfactorily resolved before foreign enterprises will invest in unilat-
eral or collaborative R&D and production activities or transfer tech-
nology in a given country.  Thus, technological innovations are not
the only changes necessary to increase a country’s attractiveness—
economic and legal innovations appear to be at least as important as
those in technology, and pose a clear challenge for economists and
lawyers.3
The Conference on Public-Private Initiatives After TRIPS
(Conference) was, as expressed by Professors Lange and Reichman,
aimed at discussing and analyzing legal innovations following the
Agreement on Trade-Related Aspects of Intellectual Property Rights
(TRIPS Agreement).4  The Conference concentrated on a new and
innovative cooperative strategy and its likely institutional framework,
the Center for Public-Private Initiatives After the TRIPS Agreement
(Center).  The Center has been designed to serve as a means for en-
1. See Rémi Barré, Relationships Between Multinational Firms’ Technology Strategies and
National Innovation Systems: A Model and an Empirical Analysis, in INNOVATION, PATENTS
AND TECHNOLOGICAL STRATEGIES 201, 206 (1996).  See generally Keith Pavitt & Pari Patel,
Technological Strategies of the World’s Largest Companies, 18 SCI. & PUB. POL. 363 (1991).
2. See generally Barré, supra note 1, at 202; Jan Maarten de Vet, Globalization and Local
and Regional Competitiveness, 13 STI REV. 89 (1993); Frédérique Sachwald, European Com-
petitiveness, the Single Market and Globalization, in EUROPEAN INTEGRATION AND COM-
PETITIVENESS 5 (Frédérique Sachwald ed., 1994).
3. See generally Lester C. Thurow, Needed: A New System of Intellectual Property Rights,
HARV. BUS. REV., Sept.-Oct. 1997, at 100-03 (demonstrating that countries must also resolve
these features in relation to intellectual property rights).
4. See Agreement on Trade-Related Aspects of Intellectual Property Rights, Apr. 15,
1994, Marrakesh Agreement Establishing the World Trade Organization, Annex 1C LEGAL
INSTRUMENTS—RESULTS OF THE URUGUAY ROUND vol. 31; 33 I.L.M. 81 (1994) [hereinafter
TRIPS Agreement].
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couraging and improving the international flow of technology and for
attracting foreign investments to a given country.  Furthermore, as an
informal amicable mediator, the Center should help to resolve differ-
ences of opinions that are linked predominantly to issues related to
intellectual property.  The bottom line of this approach will be evi-
dent in the cooperation of private parties with public institutions of
the interested country in a manner intended to optimize the use of
available intellectual property rights (IPRs), design surrogate or
complementary solutions in case of a lack of protection, and establish
specific market conditions that would allow an economically re-
warding engagement.  The whole exercise should be for the benefit of
all directly involved parties, as well as for macro-economic interests
of the respective country.
The idea for the Center is not only original and ambitious, but
also realistic enough to be eventually attained.  Professors Lange and
Reichman offered a number of convincing reasons why this idea
should indeed be attained.  This Comment will discuss several more.
However, prior to undertaking this feat, it is necessary to gain some
distance from Lange and Reichman’s basic statements concerning the
extent to which the newly established international system for the
protection of IPRs, under the TRIPS umbrella, may have a particular
economic impact on newly-industrialized and developing countries.
Although Lange and Reichman have by no means questioned the ne-
cessity and overall usefulness of the system,5 they have predicted that
it will likely result in negative consequences such as increased social
costs, rising tensions among the World Trade Organization (WTO)
members, and an increased tendency of developing and developed
countries to extensively exploit the deficiencies of the system for the
benefit of their particular interests.6  Consequently, Lange and
Reichman eventually recommend that developing countries treat the
TRIPS Agreement as set of default rules to be bargained around
within the limits provided thereunder, as this will help them regain
“some of the negotiating initiative that was lost during the multilat-
5. This view has also been cautiously expressed in a study prepared by the Secretariat of
the United Nations Conference on Trade and Development (UNCTAD): “In summary, one
can say empirically that intellectual property protection is one of a larger number of factors
influencing firms’ decisions to transfer technology to, or invest in, a particular country. . . .”
U.N. CONF. ON TRADE AND DEV., THE TRIPS AGREEMENT AND DEVELOPING COUNTRIES at
18, U.N. Doc. UNCTAD/ITE/1, U.N. Sales No. 96.II.D (1996) [hereinafter UNCTAD].
6. See J.H. Reichman & David Lange, Bargaining Around the TRIPS Agreement: The
Case for Ongoing Public-Private Initiatives to Facilitate Worldwide Intellectual Property Trans-
actions, 9 DUKE J. COMP. & INT’L L. 11, 14-15 (1998).
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eral trade negotiations of the Uruguay Round.”7
In further developing the ideas of Lange and Reichman and re-
sponding to their assertions, Part II of this Comment describes the
effects of the TRIPS Agreement’s patent protection on worldwide
trade.  Deficiencies and weaknesses in the Agreement are revealed,
and it is observed that countries will benefit unequally from resulting
shifts in their competitive market advantage.  Part III addresses the
flexibility in patent exploitation offered by Article 27 of the TRIPS
Agreement, predicting how this flexibility will benefit countries to
varying degrees and suggesting ways in which the Center may assist
them in maneuvering to their advantage within the bounds of Article
27.
II.  THE IMPACT OF THE TRIPS AGREEMENT ON
INTERNATIONAL TRADE
Two implications of the TRIPS Agreement are particularly im-
portant.  First, had the TRIPS Agreement failed to achieve parity be-
tween the extra-territorial treatment of immaterial goods and the
treatment afforded to other subject matters of international trade, se-
rious frictions in international trade relations would have unavoida-
bly resulted.  Clearly, the anomaly of an almost total lack of mini-
mum IPRs was no longer tenable.  This is particularly true in the field
of patent law, even in countries that have considerable surplus in the
balance of payments and trade and that participate in and benefit
from the globalization and integration of world markets.  It is not
possible for a country to invoke principles of territoriality and na-
tional treatment, while simultaneously claiming to justify the appro-
priation of foreign inventions within its national borders and claiming
free access and non-discriminatory treatment of goods and services in
the markets of the originators of the appropriated technology.8  Thus,
by accepting obligations under the General Agreement on Tariffs
and Trade (GATT) and TRIPS Agreement, WTO members have in
principle opened up and allowed mutual access to their markets for
both tangible and intangible goods.  In this context, process and
product inventions originating in foreign countries can be guaranteed
market access and sustained market affirmation only through the ef-
fective protection of IPRs.  More concretely, in the case of the Peo-
7. Id. at 61.
8. See Joseph Straus, Implications of the TRIPs Agreement in the Field of Patent Law, in
FROM GATT TO TRIPS: THE AGREEMENT ON TRADE-RELATED ASPECTS OF INTELLECTUAL
PROPERTY RIGHTS 160, 163-70 (Friedrich-Karl Beier & Gerhard Schricker eds., 1996).
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ple’s Republic of China (China), an effective protection of IPRs of
foreign origin was a precondition and remains an important compo-
nent of its successful trade with the European Union (EU) and the
United States.  This protection has resulted in some $40 billion of an-
nual trade balance surplus to China.  The sensitivity and fragility of
the balance between the effective protection of IPRs and interna-
tional trade is well demonstrated by the bilateral relations between
the United States and China, and by the problems the latter contin-
ues to face in its efforts to become a WTO member.9
Thus, the TRIPS Agreement has to be understood as a corner-
stone of today’s globalized research, development, production, and
trade.  It would be naive and unrealistic to believe the TRIPS
Agreement will function with few or no problems, or without the par-
ties involved trying to exploit its deficiencies.  It would, however, be
extremely dangerous and eventually detrimental if the parties in-
volved tried to deliberately circumvent or even discredit the princi-
ples underlying the TRIPS Agreement.  The TRIPS Agreement has
become a precious good not just for developed countries, but for all
actors in the global economy.  The stage of interdependence of these
actors, which has been reached in the meantime, simply requires a
good tune of the balance of all interests involved.  The TRIPS
Agreement is one of its most important and indispensable guaran-
tors.
Second, it is doubtful that developing countries and newly indus-
trialized countries (NICs), by their acceptance of the high standards
of protection of IPRs imposed by the TRIPS Agreement, will benefit
only through the TRIPS Agreement externalities.  In other words,
thanks to the TRIPS Agreement such countries will not only secure
access to world markets for their goods and services, such as textiles,
agricultural products, minerals, and shoe-wares, under non-
discriminatory conditions.10  Despite the scarce and non-reliable em-
pirical data, efficient patent protection as provided under the TRIPS
Agreement—protection that will result in increased patent activities
in NICs as well as in developing countries—will by no means be
9. For the respective statistics, see Tony Walker, China US over WTO, FIN. TIMES, Oct.
18, 1995, at 4; Tony Walker, US-China Copyright Accord ‘A Step Forward’, FIN. TIMES, June
18, 1996, at 4; Tony Walker & Jurek Martin, Last-gasp Deal Averts US-China Trade War: Bei-
jing to Tighten Enforcement Against Film and Software Industry, FIN. TIMES, June 18, 1996, at
1.  For a discussion of the trade balance between China and the member states of the European
Union, see, for example, Die Europäer wollen besseren Zugang zum chinesischen Markt,
FRANKFURTER ALLGEMEINE ZEITUNG, July 6, 1995, at 13.
10. See Straus, supra note 8, at 168.
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solely or even predominantly used by foreign patent owners to sup-
port importation monopolies.11  Rather, such patent protection will
increasingly lead to local R&D and production engagement when the
key features mentioned earlier are sufficiently favorable.
It is important not to overlook or ignore the substantial changes
that globalization has caused.  For example, this phenomenon now
offers internationally active enterprises real choice in locating their
R&D and production activities at sites where they can expect the
most comparative advantages.  This freedom of choice is inseparably
linked to the free flow of technology, capital, and goods, which can be
marketed anywhere in the world markets, irrespective of the place of
production.  Multinational enterprises, for instance, tend to set inno-
vation activities at sites with a technological specialization, and thus a
technological advantage, in their sector of activity.12  An example of
this would be the Daimler-Benz decision to develop software in In-
dia, where the human resources are comparably cheap but skillful.
According to Cantwell and Hodson, non-resident-owned research
tends to be drawn to those sectors in which a recipient country has a
comparative patenting advantage.13  The correctness of this finding
can be best observed in continental Europe through the shift of
nearly all industrial R&D activities in the field of biotechnology from
Europe to the United States and Japan.14  Although the uncertainties
around the patentability of such biotechnological inventions as hu-
man genes, transgenic animals, or plants15 may be viewed as only one
possible reason for that move, the essential influence of comparative
advantages cannot be questioned.  Thus, the provisions of European
patent law that exclude protection for plant or animal varieties16—
11. As claimed by José L. Solleiro & Elena Arriaga, Patentes en biotecnología: oportuni-
dades, amenazas y opciones para América Latina, 12 REVISTA DEL DERECHO INDUSTRIAL 126-
28 (1990).
12. See Barré, supra note 1.
13. See John Cantwell & Christian Hodson, Global R&D and UK Competitiveness, in
GLOBAL RESEARCH STRATEGY AND INTERNATIONAL COMPETITIVENESS 133-34 (Mark Cas-
son ed., 1990).
14. See, e.g., David Dickson, German Biotech Firms Flee Regulatory Climate, 244 SCI.
1251, 1251-52 (1989).
15. These uncertainties are reflected by the debate in the European Parliament on the
Proposal for a European Directive on the Legal Protection of Biotechnological Inventions.
Eventually, the European Parliament and the Council on the Legal Protection of Biotech-
nological Inventions adopted Directive 98/44/EC on July 6, 1998.  See Parliament and Council
Directive 98/44, 1998 O.J. (L 213) 13.
16. European Patent Convention, Oct. 5, 1973, art. 53(b), reprinted in JOHN P. SINNOTT,
WORLD PATENT LAW AND PRACTICE 30-32 (1994).
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and essentially all biological processes for the production of animals
and plants—place in doubt17 the patentability of hundreds of generic
inventions in transgenic plants and animals,18 and clearly present a
comparative patenting disadvantage for Europe.19  The shift of the
industrial R&D activities in this area from Europe to the United
States and Japan will also lead to the production of the respective
biotechnological products in those countries and, without the clarifi-
cations introduced by the EU Biotech Directive,20 may leave Europe
17. In its decision T 356/93 of February 21, 1995 (Plant Cells/Plant Genetic Systems), the
Technical Board of Appeal of the European Patent Office rejected a claim that related to a
non-biologically transformed plant, possessing in its genome a stable integrated foreign DNA
nucleotide sequence encoding a protein having specific useful properties, as a claim directed to
“plant varieties” and as such being banned from patent protection under Article 53(b) EPC.
See 1995 OJ Eur. Pat. Off. 545, 579 No. 40.4.  This decision has been widely criticized in legal
literature.  See, e.g., Peter Lange, Patentierungsverbot für Pflanzensorten, 1996 GEWER-
BLICHER RECHTSSCHUTZ UND URHEBERRECHT [hereinafter GRUR] [Int.] 586, 589-91; HANS-
RAINER JAENICHEN, THE EUROPEAN PATENT OFFICE’S CASE LAW ON PATENTABILITY OF
BIOTECHNOLOGICAL INVENTIONS 29 (2d ed. 1996); Tim Roberts, Patenting Plants Around the
World, 18 EUR. INTELL. PROP. REV. 531, 534-35 (1996); Alan W. White & John D. Brown,
EPC Appeal Procedures - Opinion G 03/95 (Inadmissible Referral), 18 EUROPEAN INTELL.
PROP. REV. 419, 419-21 (1996); Ulrich Schatz, Zur Patentierbarkeit gentechnischer Erfindungen
in der Praxis des EPA, 1997 GRUR [Int.] 591, 591-93; Joseph Straus, Völkerrechtliche Verträge
und Gemeinschaftsrecht als Auslegungsfaktoren des europäischen Patentübereinkommens, 1998
GRUR [Int.] 1, 10, 12-14.  However, in a similar case the Technical Board of Appeal of the
European Patent Office referred four questions related to patentability of transgenic plants per
se to the Enlarged Board of Appeals.  See Transgenic Plant/Novartis, T 1054/96-3.3.4, 1998 O.J.
Eur. Pat. Off. 511.
18. Telephone interview with Dr. Christian Gugerell, Director of the Biotech Division of
the European Patent Office (May 1997).  According to Dr. Gugerell, some 2000 patent applica-
tions (1377 for transgenic plants and 580 for transgenic animals) are pending before the Euro-
pean Patent Office.  Of these, 90% of applications are directed to animal claims per se; in the
case of applications claiming plants, the figure was 60%.
19. It should suffice to recall that claims related to plants and animals have been issued in
the United States since the late 1980s.  See Ned Hettinger, Patenting Life: Biotechnology, In-
tellectual Property, and Environmental Ethics, 22 B.C. ENVTL. AFF. L. REV. 267, 271 (1995); see
also Reid Adler, Can Patents Co-Exist with Breeder’s Rights? Developments in U.S. and Inter-
national Biotechnology Law, 17 INT’L REV. INDUS. PROP. & COPYRIGHT L. 195, 195-201
(1986); Robert P. Merges, Intellectual Property in Higher Life Forms and Controversial Tech-
nologies, 47 MD. L. REV. 1051, 1052, 1068-75 (1988).
20. Although under Article 4(1)(a) of the Directive, plant and animal varieties remain
excluded from patent protection, paragraph two of that Article makes it clear that “inventions
which concern plants or animals shall be patentable if the technical feasibility of the invention
is not confined to a particular plant or animal variety.”  Parliament and Council Directive
98/44, supra note 15, art. 4(1)(a).  Thus, it would appear that generic inventions in plants are
explicitly declared patentable subject matter.  Further support for this proposition is the clarifi-
cation contained in Recital 31, according to which a plant grouping which is characterized by a
particular gene (and not its whole genome) is not excluded from patentability even if it com-
prises new varieties of plants.  See id. Recital 31 at 25.  The impact of this Directive on the prac-
tice of the European Patent Office, however, remains to be seen.  See generally Straus, supra
note 17 (detailing the complex relationship between the European Patent Convention, the
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as predominantly a market for most biotechnological products.
Also, in the areas of pharmaceuticals and chemicals, the exam-
ples of Japan21 and Korea22 have demonstrated that the introduction
of an effective patent protection has eventually led to increased R&D
activities and to an improved economic performance of those coun-
tries.  Moreover, in the past, most developing countries in which
there was no protection of chemicals, pharmaceuticals, or biotech-
nological inventions, were barely in a position to successfully use the
unprotected technologies locally.  For example, until recently, bio-
technological inventions and classical plant breeding activities were
completely unprotected in Brazil.23  Consequently, with the exception
of breeding hybrids, foreign companies did not engage in such activi-
ties in Brazil.  At the same time, local plant breeding activities were
more than modest.  In other words, it appears the lack of protection
was a clear macro-economic disadvantage to Brazil.  However, under
the conditions altered by the TRIPS Agreement, some companies in
NICs and developing countries will be negatively affected.24  In par-
ticular, generic drug producers, who previously benefited from the
lack of protection for pharmaceuticals, will now experience such
negative effects.25  However, under specific patent protections, losses
of such companies may not be equated to damages to, or disadvan-
tages of, the respective national economy as a whole.26
Therefore, under the new conditions of globalization, for coun-
tries that attract foreign investments in R&D and production activi-
ties, the availability of an effective patent protection in a given coun-
try should be viewed, not as the scapegoat for increased social costs,
but as a “comparative patenting advantage.”  A comparative patent-
European Union, and other international agreements, including TRIPS).
21. See Guntram Rahn, The Role of Industrial Property in Economic Development:  The
Japanese Experience, 14 INT’L REV. IND. PROP. & COPYRIGHT L. 449, 465 (1983).  From 1940
to 1975, Japanese companies introduced ten pharmaceutical products into the Japanese mar-
ket; in the first eight years since the introduction of product patent protection for pharmaceuti-
cals in 1976, more than eighty Japanese pharmaceutical products have reached the market.  See
Special Questions of Newly Emerging Technologies - Biotechnology, at E36 WIPO Doc.
F/IPCA/9 (Aug. 1989).  See generally Mark D. Dibner, Biotechnology in Pharmaceuticals: The
Japanese Challenge, 229 SCIENCE 1230 (1985).
22. See Siegfried Greif, Patents and Economic Growth, 18 INT’L REV. IND. PROP. &
COPYRIGHT L. 191, 211 (1987) (describing the Korean experience).
23. See Carlos M. Correa, Implementing the TRIPs Agreement in the Patent Field - Options
for Developing Countries, 1 J. WORLD INTELL. PROP. 75, 79 (1998).
24. See UNCTAD, supra note 5, at 15 (considering the costs and benefits for developing
countries that stem from the TRIPS Agreement).
25. See id.
26. See id.
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ing advantage is especially evident in countries where skilled human
resources, areas of excellence, lower operating costs, or special or
unique circumstances—such as genetic resources—can be found.27
III.  MANEUVERING SPACE FOR THE CENTER: PUBLIC-
PRIVATE INITIATIVES AND “COMPARATIVE PATENTING
ADVANTAGES”
After the TRIPS Agreement it might be possible to doubt the
availability of pure comparative patenting advantages because Arti-
cle 27(1) of the Agreement requires WTO members to make patents
available for both product and process inventions in all fields of tech-
nology, provided the usual patentability requirements are met.28
However, due to the influence of Europe and the developing
countries, the TRIPS Agreement allows members to exclude patent
protection of inventions under certain circumstances of products the
“commercial exploitation of which is necessary to protect ordre pub-
lic or morality, including to protect human, animal or plant life or
health or to avoid serious prejudice to the environment, provided
that such exclusion is not made merely because the exploitation is
prohibited by domestic law.”29
This part of the TRIPS Agreement established the first interna-
tional guidance as to which regulations of a given legal order consti-
tute ordre public: regulations that are necessary to protect the life or
health of humans, animals, or plants or to avoid serious damage to
the environment.30  In contrast, regulations or prohibitions anchored
in national laws of the members will not suffice.31  As a consequence,
the TRIPS Agreement does not prohibit members from obstructing
certain technological developments or exploiting their results in cer-
tain extremely sensitive areas.  For example, a member could, within
the context of patent law, prohibit exploitation of pharmaceutical
production and marketing of plant or animal biotechnology.32  Thus,
patenting of such inventions can be precluded only if the relevant
country refrains from commercial exploitation, such as marketing,
27. See generally Barré supra note 1; Cantwell & Hodson, supra note 13.




32. Plant or animal biotechnology is the production and use of transgenic animals or plants
that are either resistant to pesticides, insecticides, insects, or certain environmental influences
such as humidity or drought.
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distribution, or sale of such inventions.33
Also, under the obvious influence of the exclusionary provisions
existing under the European patent law, the TRIPS Agreement per-
mits its members to exclude altogether from patentability
“diagnostic, therapeutic and surgical methods for the treatment of
humans and animals.”34  As already stated, this provision cannot be
interpreted to mean that appliances or diagnostic means used or
therapeutic means administered in such methods may remain ex-
cluded from patent protection.35  Article 70(8) of the TRIPS Agree-
ment clearly indicates that Article 27(1) obliges WTO members to
afford protection for pharmaceutical products, subject to the transi-
tional arrangements.36  Since somatic gene therapy in in vivo and ex
vivo is to be viewed as a combination of patentable methods for pro-
ducing new pharmaceutically active substances, by employing the
special means of recombinant DNA technology and the products ob-
tained as pharmaceutically active substances that function at the
molecular level,37 the patentability of intellectual property such as
somatic gene therapy for curing cancer or inherited monogenic de-
fects may not be affected by this provision.38
A further influence of the European patent law is reflected in
Article 27(3)(b) of the TRIPS Agreement, which allows WTO mem-
bers to exclude from patentability “plants and animals other than mi-
cro-organisms, and essentially biological processes for the production
of plants or animals other than non-biological and micro-biological
processes.”  However, this provision makes it mandatory that mem-
bers provide for some kind of protection for plant varieties.39  This
may be made available as patent protection or under an effective sui
generis system, or under a combination of both systems.  The wording
of this obligation, which leaves the choice of the protection system
entirely to the members, reflects on the one hand the broad range of
existing systems, ranging from the United States where plant varieties
may be protected by patents or by specific plant variety protection
33. See Carlos M. Correa, The GATT Agreement on Trade-Related Aspects of Intellectual
Property Rights: New Standards for Patent Protection, 16 EUR. INTELL. PROP. REV. 327, 328
(1994); Straus, supra note 8, at 182.
34. TRIPS Agreement, supra note 4, art. 27(3)(a).
35. See Straus, supra note 8, at 183; see also Correa, supra note 33.
36. See Straus, supra note 8, at 184.
37. See Joseph Straus, Patentrechtliche Probleme der Gentherapie, 1996 GRUR [Int.] 10,
12.
38. See id.
39. See TRIPS Agreement, supra note 4, art. 27.
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rights or even by special plant patents,40 to the EU countries where
plant variety protection is confined to specific variety protection sys-
tems only.41  On the other hand, however, the wording also reflects
the fact that the 1991 revision of the International Convention for the
Protection of New Varieties of Plants (UPOV) abandoned the so-
called prohibition of double protection.  The possibility of excluding
plant varieties from patent protection as permitted under the TRIPS
Agreement and the previous resistance of many developing countries
to provide any protection at all in this field, will most likely result in
either the adherence of those countries to the 1978 version of the
UPOV Convention—which lags well behind the 1991 Revision
Act42—or the creation of sui generis protection according to their own
concepts.43
While the application of the explicit exceptions will result in dif-
ficulties similar to those of Europe, other important issues are not
even addressed in the TRIPS Agreement.  For example, this is true
for the patentability of computer programs and the important demar-
cation between the notion of patentable invention and unpatentable
discovery.44  The fact that the latter issue is left to the members to re-
solve may not in principle place into question the patentability of
naturally occurring substances such as DNA and cell lines.  If micro-
40. See, e.g., Reid G. Adler, Can Patents Coexist with Breeders’ Rights? Developments in
U.S. and International Biotechnology Law, 17 INT. REV. IND. PROP. & COPYRIGHT L. 195, 199-
210 (1986).
41. See discussion supra note 20.
42. See generally NOEL BYRNE, COMMENTARY ON THE SUBSTANTIVE LAW OF THE 1991
UPOV CONVENTION FOR THE PROTECTION OF PLANT VARIETIES (1992) (discussing the In-
ternational Convention for the Protection of New Varieties of Plants (UPOV), 1991 Revision
Act).  Whether the UPOV 1978 Revision Act may be viewed as complying with the require-
ments set out in Article 27(3)(b) TRIPS Agreement is not discussed at length here.  However,
in view of the UPOV’s Article 4(3)(b)(iii), which allows contracting parties, even after a transi-
tory period of eight years, to provide protection for only twenty-four “genera” or species of
plants, thus leaving unprotected a broad area of plant breeding activities, serious doubts may
be expressed as to whether such in part non-existing protection may be called effective. See
Joseph Straus, The Relationship Between Plant Variety Protection and Patent Protection for
Biotechnological Inventions from an International View Point, 18 INT. REV. IND. PROP. &
COPYRIGHT L. 723, 731 (1987) (discussing the unprotected activities in Europe in the 1980s).
43. This third option has been considered or suggested.  See S.K. Verma, TRIPs and Plant
Variety Protection in Developing Countries, 17 EUR. INTELL. PROP. REV. 281, 288-89 (1995);
Correa supra note 33, at 334.  Also, the latest Indian draft legislation on plant breeders’ rights
seemingly follows that path.  See Biswajit Dhar & Sachin Chatuvedi, Introducing Plant Breed-
ers’ Rights in India – A Critical Evaluation of Proposed Legislation, 1 J. WORLD INTELL PROP.
245, 249-260 (1998).
44. See TRIPS Agreement, supra note 4, art. 27 (defining patentable inventions as
“products or processes, in all fields of technology, provided that they are new, [and] involve an
inventive step and are capable of industrial application”).
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organisms are declared subject matter eligible for mandatory patent
protection, naturally occurring biochemical substances such as DNA,
reasoning from the greater to the smaller, should also to be regarded
as subject matter for which WTO members must offer product patent
protection.  Thus, information embodied in genetic resources can be
excluded from patent protection only under the conditions set out in
Article 27(2)-(3) of the TRIPS Agreement.  From the lack of a defi-
nition of the concept of invention in the TRIPS Agreement, it may
not be generally concluded that WTO members, whether they are
developed or developing countries,45 could legitimately follow a defi-
nition of invention that broadly excludes materials pre-existing in na-
ture from patentability.46
Whether Article 27(1) of the TRIPS Agreement will be able to
fulfill its intended purpose, despite its vagueness, as previously dis-
cussed, will depend partly on the manner in which it is implemented
in legislation and practice in the member countries.  Furthermore,
stimuli and calls for further precision in the text, such as the inclusion
of previously unpatentable creations under the notion of invention,
and in the case of computer programs, will depend on the necessity of
protecting the creators of such subject matter.  This contingency will
be especially true in those member countries who are the leading
powers in the relevant field of activity.47  Regarding the allowable ex-
clusion from patentability of plants and animals, a review of this pro-
vision will take place four years after entry into force of the WTO
Agreement, by 1999.
As China was at the center of interest during the Conference, it
is important to analyze China’s patent law48 to superficially examine
45. This requirement applies to developing countries only after the expiration of the tran-
sitory period.  See TRIPS Agreement, supra note 4, art. 65.
46. See, e.g., UNCTAD, supra note 5, at 34; Correa, supra note 23 (referring to Art. 6(b)
of Decision 344 of the Andean Group and Art. 6(g) of the new Argentine patent law, which set
out that substances pre-existing in nature and their replications, and any kind of life material or
substances already existing in nature, respectively, do not constitute an “invention”).  In con-
trast, in Egypt a patent has already been issued on an insecticidal gene that is isolated from a
bacterium (Bacillus thuringiensis) indigenous to Egypt.  See Atef el-Azab, Egypt, in IN-
TELLECTUAL PROPERTY RIGHTS IN AGRICULTURAL BIOTECHNOLOGY 65, 71 (F.H. Erbisch &
K.M. Maredia eds., 1998).
47. See J.H. Reichman, The TRIPs Component of the GATT’s Uruguay Round: Competi-
tive Prospects for Intellectual Property Owners in an Integrated World Market, 4 FORDHAM
INTELL. PROP. MEDIA & ENT. L.J. 171, 198-203 (1993).
48. See Zhonghua Renmin Gongheguo Zhuanlifa [Patent Law of the People’s Republic of
China] FAGUI HUIBIAN 1992, translated in 2 CHINA L. FOREIGN BUS. (CCH) P 11-600 (1993)
(adopted March 12, 1984, amended September 4, 1992).
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its compatibility with the patent protection of the TRIPS Agreement.
It appears that only the complete lack of protection of plant varieties
under Chinese patent law contradicts TRIPS obligations.49  This defi-
ciency, however, seems to be cured by the Law on the Protection of
New Varieties of Plant Strains.50
However, this does not mean that a good opportunity does not
exist for the Center for Public-Private Initiatives After the TRIPS
Agreement to be involved and to offer its services.  There are many
good reasons to be involved: On the one hand, China’s patent law is
clearly designed after the European patent model, excluding from
patent protection, among others, methods for the diagnosis or for the
treatment of diseases, and animal and plant varieties.51  Thus, China
cannot claim, at least not for the area of biotechnology, to dispose of
“comparative patenting advantages.”  On the other hand, to stay with
the same area of technology, China disposes of a number of centers
of excellency in plant breeding and also animal breeding.  Moreover,
in the province of Yunnan alone, more than 18,000 plant types exist.52
Thus, China is a country with rich genetic resources, which are gain-
ing increasing importance in the areas of plant and animal breeding,
medicine, pharmaceuticals, chemicals, and protection of environ-
ment.53
In this context, under Article 3 of the Convention on Biological
Diversity,54 the sovereign rights of states over their natural resources
are explicitly recognized; including their authority to determine ac-
cess to genetic resources by national legislation.55  Thus, notwith-
standing the statement that “Each Contracting Party shall endeavor
to create conditions to facilitate access to genetic resources for envi-
ronmentally sound uses by other Contracting Parties and not to im-
pose restrictions that run counter to the objectives of this Conven-
49. See id.
50. See The Law on the Protection of New Varieties of Plant Strains, published in 12
ZHONGHUA RENMIN GONGHEGUO GUOWUYUAN GONGBAO [Gazette of the State Council of
the People’s Republic of China] 550 (1997) (adopted March 1997, entered into force October
1997); see also 1997 GRUR [Int.] 855.
51. See id.
52. See James Harding, Bio-Resources Bloom in Yunnan, FIN. TIMES, July 2, 1997, at 37.
53. In China, for example, vegetables such as tomatoes, that have been genetically engi-
neered for resistance to viruses, have been on the market since 1993, thus years ahead of
Europe or even the United States.  See, e.g., Anne S. Moffat, Developing Nations Adopt Bio-
tech for Own Needs, 265 SCIENCE 186 (1994).
54. See Convention on Biological Diversity, June 5, 1992, 31 I.L.M. 818 [hereinafter Bio-
diverisity Convention].
55. See id. art. 15(1).
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tion,” the foundation for ownership in genetic resources on an inter-
national scale has been established.56  Access to genetic resources un-
der Article 15(3)-(5) requires prior informed consent,57 and must be
on mutually agreed terms.  Moreover, the country providing genetic
resources is entitled to share benefits from the commercial use of its
genetic resources, such sharing based upon mutually agreed terms.58
In this context, it is important to understand the double nature of ge-
netic resources: as phenotypes (individual plants, animals or micro-
organisms) they traditionally constitute private (tangible) goods; as
genotypes (information embodied in the genetic constitutions of a
plant, animal or micro-organism) they a priori conform to the defini-
tion of public good.  However, genotypes can possess exclusivity.
This holds true if the access to genotypes is limited by either tangible
property ownership or by IPRs, such as patents or plant breeders’
rights.59  Thus, the developments that led to patenting plants, animals,
micro-organisms, and other biological materials under the patent law
provisions of the developed world have made genetic resources po-
tentially direct or—more probably—indirect subject matter of intel-
lectual property.60  The bargaining position of the host countries of
genetic resources is further strengthened by Article 16 of the Con-
vention on Biodiversity under which an obligation for each Con-
tracting Party was established to undertake “to provide and/or facili-
56. Id. art. 15(2).  Due to the balanced obligations of host countries, however, the right of
the states to control access to genetic resources is not an absolute right.  See Access to Genetic
Resources and Benefit Sharing: Legislative, Administrative and Policy Information, Conference
of the Parties to the Convention of Biological Diversity, 2d mtg., U.N. Doc.
UNEP/CBD/COP/2/13 (1995); see also LYLE GLOWKA, ET AL., A GUIDE TO THE CONVENTION
ON BIOLOGICAL DIVERSITY, INTERNATIONAL UNION FOR THE CONSERVATION OF NATURE
AND NATURAL RESOURCES (IUCN) 26 (1994).
57. See Biodivesity Convention, supra note 54, art 15(5).  “Prior informed consent” in-
volves, in chronological order:
(i)  consent of the Contracting Party providing genetic resources;
(ii)  based on information provided by the Party interested in access to and use of ge-
netic resources; and
(iii)  prior to consent for access being granted, the provider has the authority to re-
quire information, inter alia, on the subsequent use, etc., of genetic resources.
Joseph Straus, Biodiversity and Intellectual Property, 1998/IX AIPPI Y.B. 99, 104-105.
58. See id. art. 15(6)-(7).  Terms are mutually agreed upon if they are reciprocally ac-
cepted.  See Access to Genetic Resources, Conference of the Parties to the Convention of Bio-
logical Diversity, 3d mtg., U.N. Doc. UNEP/CBND/COP/3/20 (1996).
59. See Roger A. Sedjo, Property Rights, Genetic Resources and Biotechnological Change,
35 J.L. & ECON. 199, 201, 206-08 (1992).
60. See Joseph Straus, The Rio Biodiversity Convention and Intellectual Property, 24 IIC:
INTERNATIONAL REVIEW OF INDUSTRIAL PROPERTY AND COPYRIGHT LAW 602, 603-04
(1993).
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tate access for and transfer to other Contracting Parties” of, inter
alia, technologies that make use of genetic resources or are relevant
to the conservation of biological diversity and the sustainable use of
its components.61  Moreover, Article 16(2) further clarifies this obli-
gation by stating that said access and transfer must be provided
and/or facilitated under fair and most favorable terms, including on
concessional and preferential terms when mutually agreed.  This new
situation is well reflected by novel forms of cooperation between
companies and universities interested in prospecting for pharmaceu-
tical use chemicals in plants, animals, and insects of the tropics, and
public or private institutions in countries disposing of such genetic re-
sources.  A number of well-known examples exists for such coopera-
tive agreements between U.S. companies and universities and pub-
licly administered or funded institutions in Argentina, Brazil,
Cameroon, Chile, Costa Rica, Mexico, Nigeria, and Suriname.62  The
basic design of the agreements is to establish research activities in the
host countries (in cooperation with local institutions) to screen bio-
logical materials, pay a lump sum for the access to that material, and
provide for the sharing of expected revenues from the commercial
product in the form of royalties.63
Although it is premature to predict the final benefit, it should be
beyond doubt that in this area countries like China, private compa-
nies, and academic institutions from the developed world should see
a new field of activity with great potential for the future in which in-
tellectual property rights will play an important role.  To some extent
it has not yet been fully realized by the host countries of genetic re-
sources that the only effective form of protection for the interna-
tional exploitation of these resources are patents or other forms of
IPRs.  This is due to the specific trait of self-reproduction of those re-
sources.  Once biological material has left the country, it is practically
out of control of the original owner of the tangible good.  Therefore,
only IPRs can control the exploitation and secure a reward.64  In view
of the fact that China is not currently taking full advantage of its rich
61. Biodiversity Convention, supra note 54, art. 16(1).
62. See, e.g., Joshua. P. Rosenthal, Equitable Sharing of Biodiversity Benefits: Agreements
on Genetic Resources, in OECD PROCEEDINGS: INVESTING IN BIOLOGICAL DIVERSITY: THE
CAIRNS CONFERENCE 253 (1997).
63. For more details, see generally Thomas Eisner, Chemical Prospecting: A Global Im-
perative, 138 PROC. AM. PHIL. SOC’Y 385 (1994); Rosenthal, supra note 62.
64. See R.S. CRESPI & JOSEPH STRAUS, INTELLECTUAL PROPERTY, TECHNOLOGY
TRANSFER AND GENETIC RESOURCES, AN OECD SURVEY OF CURRENT PRACTICES AND
POLICIES 15 (1996).
FINALSTRAUS2.DOC 04/02/99  2:29 PM
106 DUKE JOURNAL OF COMPARATIVE & INTERNATIONAL LAW [Vol 9:91
genetic resources or its highly skilled human resources in the area of
plant and animal breeding and molecular biology and genetics, the
Center could find in this area one of its first fields of activity.  There-
fore, the Center should do as follows: focus on the search for compe-
tent public institutions in China entitled to negotiate the access and
exploitation of genetic resources; discuss the legal problems linked to
the access and exploitation of those resources and the access of the
respective biotechnology—especially related to the question of na-
tional legislation specifically dealing with these issues;65 establish links
with private parties interested in chemical prospecting; and help es-
tablish local research facilities necessary for screening activities as the
basis for further research and development.  The Center may also
serve as a neutral mediator in helping the responsible Chinese
authorities to better understand the following issues: the economic
implications of the existing exclusionary provisions related to bio-
technological innovation; the potential comparative competitive posi-
tion of China in globalized research, development, and production
activities; and the necessity of balanced and attractive legislation on
access to and benefit sharing from genetic resources for a prosperous
development of biotechnology research industry in China.
IV.  CONCLUSION
In sum, the idea of a Center on Public-Private Initiatives After
the TRIPS Agreement is a sound one.  Such a center could essentially
contribute to an optimized use of IPRs for an economically well bal-
anced benefit of developed countries, developing countries, as well as
NICs.  However, all of the involved parties have to understand and
accept the TRIPS Agreement as one of the cornerstones of present
international trade and a guarantor of its future.  Moreover, such par-
ties should also become acquainted with the idea that strong intellec-
tual property protection is to be viewed as an increasingly important
comparative advantage in the current globalized world, which should
65. So far, only the Philippines, see Exec. Order No. 247 of 1995, Prescribing Guidelines
and Establishing a Regulatory Framework for the Prospecting of Biological and Genetic Re-
sources, their By-Products and Derivatives, for Scientific and Commercial Purposes, and other
Purposes, with Implementing Rules and Regulations on the Prospecting of Biological and Ge-
netic Resources of 1996 (Phil.), and the five Latin-American States forming the so-called
“Andean Pact” (Venezuela, Columbia, Bolivia, Ecuador, and Peru), see Decision 391 On The
Common System on Access to Genetic Resources, have introduced comprehensive legislation in
this area.  For more details and legislative endeavors of some other countries, see Access to
Genetic Resources, Conference of the Parties to the Convention of Biological Diversity, 3d
mtg., U.N. Doc. UNEP/CBND/COP/3/20 (1996).
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be used to the best possible extent.  The case of genetic resources
could serve as a good example.
